Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stanislas Pol

Showing results (301-310 of 441) with videos related to

Pageof 45
Sort By:
Hepatology International|August 4, 2022
Diversity of the nucleic acid forms of circulating HBV in chronically infected patients and its impact on viral cycleJules Sotty, Pierre Bablon, Bouchra Lekbaby, et al.
Infectious Diseases and Therapy|April 8, 2026
Efficacy and Safety of Glecaprevir/Pibrentasvir in Participants with Chronic HCV Infection and Comorbidities or Multiple Concomitant Medications: An Integrated AnalysisCurtis Cooper, Shweta A Raina, Lisa Johnson, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 11, 2014
Effectiveness and cost-effectiveness of immediate versus delayed treatment of hepatitis C virus-infected patients in a country with limited resources: the case of EgyptDorothée Obach, Sylvie Deuffic-Burban, Gamal Esmat, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|September 14, 2021
Late presentation for HCV care: Time to target people with diabetes and/or hazardous alcohol use (ANRS CO22 HEPATHER cohort)Melina Santos, Camelia Protopopescu, Elizabeth Delarocque-Astagneau, et al.
Journal of Medical Virology|July 24, 2009
Response to pegylated interferon alfa-2a and ribavirin in chronic hepatitis C genotype 4Hesham El Makhzangy, Gamal Esmat, Mohamed Said, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|May 21, 2011
Pharmacological exposure to ribavirin: a key player in the complex network of factors implicated in virological response and anaemia in hepatitis C treatmentVéronique Loustaud-Ratti, Paul Carrier, Annick Rousseau, et al.
The Lancet. Gastroenterology & Hepatology|June 4, 2017
Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4-5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trialAnnette Bruchfeld, David Roth, Paul Martin, et al.
BMC Infectious Diseases|November 17, 2020
Acceptability of on-site rapid HIV/HBV/HCV testing and HBV vaccination among three at-risk populations in distinct community-healthcare outreach centres: the ANRS-SHS 154 CUBE studyRuxandra Calin, Véronique Massari, Gilles Pialoux, et al.
JHEP Reports : Innovation in Hepatology|May 6, 2022
Severe liver fibrosis in the HCV cure era: Major effects of social vulnerability, diabetes, and unhealthy behaviorsPatrizia Carrieri, Fabrice Carrat, Vincent Di Beo, et al.
Hepatology (Baltimore, Md.)|May 20, 2024
Effectiveness and safety of glecaprevir/pibrentasvir for 8 weeks in the treatment of patients with acute hepatitis C: A single-arm retrospective studyStanislas Pol, Alexander J Thompson, Michelle Collins, et al.
Pageof 45

Showing results (301-310 of 441) with videos related to

Sort By:
Pageof 45
Hepatology International|August 4, 2022
Diversity of the nucleic acid forms of circulating HBV in chronically infected patients and its impact on viral cycleJules Sotty, Pierre Bablon, Bouchra Lekbaby, et al.
Infectious Diseases and Therapy|April 8, 2026
Efficacy and Safety of Glecaprevir/Pibrentasvir in Participants with Chronic HCV Infection and Comorbidities or Multiple Concomitant Medications: An Integrated AnalysisCurtis Cooper, Shweta A Raina, Lisa Johnson, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 11, 2014
Effectiveness and cost-effectiveness of immediate versus delayed treatment of hepatitis C virus-infected patients in a country with limited resources: the case of EgyptDorothée Obach, Sylvie Deuffic-Burban, Gamal Esmat, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|September 14, 2021
Late presentation for HCV care: Time to target people with diabetes and/or hazardous alcohol use (ANRS CO22 HEPATHER cohort)Melina Santos, Camelia Protopopescu, Elizabeth Delarocque-Astagneau, et al.
Journal of Medical Virology|July 24, 2009
Response to pegylated interferon alfa-2a and ribavirin in chronic hepatitis C genotype 4Hesham El Makhzangy, Gamal Esmat, Mohamed Said, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|May 21, 2011
Pharmacological exposure to ribavirin: a key player in the complex network of factors implicated in virological response and anaemia in hepatitis C treatmentVéronique Loustaud-Ratti, Paul Carrier, Annick Rousseau, et al.
The Lancet. Gastroenterology & Hepatology|June 4, 2017
Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4-5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trialAnnette Bruchfeld, David Roth, Paul Martin, et al.
BMC Infectious Diseases|November 17, 2020
Acceptability of on-site rapid HIV/HBV/HCV testing and HBV vaccination among three at-risk populations in distinct community-healthcare outreach centres: the ANRS-SHS 154 CUBE studyRuxandra Calin, Véronique Massari, Gilles Pialoux, et al.
JHEP Reports : Innovation in Hepatology|May 6, 2022
Severe liver fibrosis in the HCV cure era: Major effects of social vulnerability, diabetes, and unhealthy behaviorsPatrizia Carrieri, Fabrice Carrat, Vincent Di Beo, et al.
Hepatology (Baltimore, Md.)|May 20, 2024
Effectiveness and safety of glecaprevir/pibrentasvir for 8 weeks in the treatment of patients with acute hepatitis C: A single-arm retrospective studyStanislas Pol, Alexander J Thompson, Michelle Collins, et al.
Pageof 45